te Boekhorst Paul Francis Olivier's Form 4 filing
Immucell Corp (ICCC) · filed Jun 22, 2026
- Accession no.
- 0001437749-26-021258
- Filed
- Jun 22, 2026
- Trade date
- Jun 18, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $76.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| te Boekhorst Paul Francis OlivierCIK 0002095704 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Common Stock, par value $.01 per share | PPurchaseAcquired | +8,000 | $9.50 | +$76,000 | 17,785 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.